OncoMatch/Clinical Trials/NCT05930665

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Is NCT05930665 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin for pleural mesothelioma.

Phase 2RecruitingSun Yat-sen UniversityNCT05930665Data as of May 2026

Treatment: Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin — Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Mesothelioma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate haematological function

Kidney function

adequate renal function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify